– Non-dilutive financing facility, plus $312M existing cash on hand as of June 30, 2022, gives atai access to up to $487M to continue developing next generation mental health treatments – Flexible draw availability provides optionality to optimize liquidity and capital structure moving forward NEW YORK and BERLIN, Aug. 15, 2022 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”)…


Previous articleField Trip Announces Closing of Plan of Arrangement and $19.9 Million Private Placement Financing
Next articleatai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update